Lilly, Galapagos Put Some Trials On Hold Due To Coronavirus Concerns

Biopharma companies struggle with which trials, if any, to pause or delay. Lilly said it wants to ease the burden on health care facilities, while Galapagos said its choice is related to patient safety.

COVID-19 SARS,Coronaviridae , SARS-CoV, SARSCoV, virus 2020 , MERS-CoV ,chinese virus 2019-nCoV
Lilly and Galapagos have paused certain trials due to coronavirus-related concerns

Eli Lilly & Co. and Galapagos NV are among the latest companies to disclose that they have paused enrollment in or are delaying the start of clinical trials for drug candidates due to COVID-19-related concerns. However, they will not be the last, since biopharmaceutical firms globally are struggling with whether to halt ongoing studies or wait to initiate new trials.

Assessments will be made on a case-by-case basis depending on many factors, including whether clinical trial participation could be the difference between life or death for some patients, whether patients’ immune systems could handle a COVID-19 infection, and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D